Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada

Inclusion criteria

• Willing to sign an Informed Consent form.
• Clinical diagnosis of ocular hypertension, exfoliative open-angle or pigment dispersion glaucoma in at least one eye (study eye).
• Be on a stable IOP lowering regimen within 30 days of Screening Visit.
• IOP considered to be safe, in both eyes, in such a way that should assure clinical stability of vision and the optic nerve throughout the study period.
• Willing to discontinue the use of COMBIGAN® prior to receiving the study drug at Visit 1.
• IOP of between 19 and 35 mmHg in at least one eye (which would be the study eye) while on brimonidine/timolol fixed combination therapy.
• Best corrected visual acuity of 6/60 (20/200 Snellen, 1.0 logMAR) or better in each eye.
• Willing to follow instructions and able to attend required study visits.
• Other protocol-defined inclusion criteria may apply.

Exclusion criteria

• Known history of hypersensitivity to any component of the preparations used in this study.
• Presence of primary or secondary glaucoma not listed in inclusion criterion #2.
• History of ocular herpes simplex.
• Abnormality preventing reliable applanation tonometry.
• Corneal dystrophies.
• Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye. Blepharitis or non-clinically significant conjunctival injection is allowed.
• Intraocular conventional surgery or laser surgery in study eye(s) less than 3 months prior to the Screening Visit.
• Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
• Progressive retinal or optic nerve disease from any cause.
• Women of childbearing potential not using reliable means of birth control for at least 1 month prior to the Screening/Baseline Visit.
• Pregnant or lactating.
• Other protocol-defined exclusion criteria may apply.